The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study.

ABSTRACT:

Background

Systemic lupus erythematosus (SLE) is associated with increased risk of cancer and the mechanism remains unclear. Here, we examined the level of auto-antibodies and disease activity index scores in SLE patients with cancers and analyzed whether medications for SLE management might contribute to the higher cancer risk in SLE patients.

Methods

In this retrospective study, we carried out a nested case-control study in a large cohort of SLE patients. We screened 5858 SLE patients to identify the newly diagnosed and yet to be treated cancers. The following clinical features were evaluated: auto-antibodies levels, SLE disease activity index scores, and previous medication used for SLE management. Systemic glucocorticoid, cyclophosphamide, hydroxychloroquine (HCQ), metho

SUBMITTER: Guo J 

PROVIDER: S-EPMC7318532 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature